Miniatura

Fitxers

725957.pdf (213.97 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2022-08-05

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/190046

Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish primary cutaneous lymphoma registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/jdv.18563

Resum

Background: Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Results: Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. Conclusions: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.

Matèries

Limfomes, Cèl·lules T, Quimioteràpia

Matèries (anglès)

Lymphomas, T cells, Chemotherapy

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MUNIESA MONTSERRAT, Cristina, GALLARDO, F. (fernando), GARCÍA-DOVAL, Ignacio, ESTRACH PANELLA, Ma. teresa (maría teresa), COMBALIA, Andrea, MORILLO, Mercedes, DE LA CRUZ-VICENTE, Fátima, MACHAN, Salma, MOYA-MARTÍNEZ, Cristina, ROVIRA, Roger, SANCHEZ-GONZALEZ, Blanca, ACEBO, Elvira, AMUTIO, Elena, PEÑATE, Yerai, LOSADA-CASTILLO, Maria del carmen, GARCIA-MURET, Maria p., IZNARDO, Helena, ROMÁN-CURTO, Concepción, CAÑUETO, Javier, FERNÁNDEZ-DE-MISA, Ricardo, FLÓREZ, Ángeles, IZU, Rosa, TORRES-NAVARRO, Ignacio, ZAYAS, Ana, PÉREZ-PAREDES, Gema, BLANES, Mar, YANGUAS, J. ignacio, PÉREZ-FERRIOLS, Amparo, CALLEJAS-CHARAVIA, Marta, ORTIZ-ROMERO, Pablo luis, PÉREZ GIL, Amalia, PRIETO-TORRES, Lucia, GONZÁLEZ BARCA, Eva, SERVITJE BEDATE, Octavio. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish primary cutaneous lymphoma registry. _Journal of the European Academy of Dermatology and Venereology_. 2022. [consulta: 21 de gener de 2026]. ISSN: 0926-9959. [Disponible a: https://hdl.handle.net/2445/190046]

Exportar metadades

JSON - METS

Compartir registre